Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a
company pioneering a single-molecule protein analysis platform for
quantifying the proteome, today announced the appointment of Emma
Lundberg, Ph.D. to its Scientific Advisory Board (SAB), effective
today.
Dr. Lundberg brings more than a decade of experience at the
interface of affinity reagents, bioimaging, proteomics, and
artificial intelligence. She is currently Professor in cell biology
proteomics at KTH Royal Institute of Technology, Sweden, and
Director of the Cell Atlas of the Human Protein Atlas, an
international proteomics and cell mapping project. Dr. Lundberg has
co-authored key scientific publications on the human proteome, cell
biology, imaging, and their use of emerging technologies including
deep learning and massive-scale citizen science. She is a former
visiting Associate Professor at Stanford School of Medicine and the
Chan-Zuckerberg Biohub.
“A true pioneer in the field of spatial proteomics, Emma
continues to unveil fundamental aspects of human cell biology that
are vital to understanding and addressing disease,” said Parag
Mallick, Ph.D., co-founder and Chief Scientist of Nautilus. “We are
pleased to welcome her to our SAB as we seek to unlock the
complexity of the proteome and significantly advance the way we
research and understand human health.”
Dr. Lundberg also holds the position of Director of the Cell
Profiling facility at the Science for Life Laboratory (SciLifeLab)
in Sweden. An advocate of citizen science, Dr. Lundberg founded
game development company Mindforce Game Lab in 2017 to advance the
use of gaming for science and health applications including
personalized medicine and mental health. She received her M.Sc. and
Ph.D. in Biotechnology from KTH Royal Institute of Technology.
“Nautilus’ exceptional leadership team and SAB are uniquely
capable of introducing the first large-scale, single-molecule
platform designed to comprehensively quantify the proteome,” said
Dr. Lundberg. “I’m thrilled to join their mission to democratize
access to the proteome with breakthrough speed, simplicity,
accuracy, and versatility that can revolutionize biomedical
research from clinical diagnostics and therapeutics to basic
science research.”
Dr. Lundberg joins a Scientific Advisory Board of renowned
proteomics leaders:
Ruedi Aebersold,
Ph.D. is Professor of Systems Biology at the Institute of
Molecular Systems Biology in ETH Zurich (IMSB), a pioneer in the
field of proteomics, co-founder of several companies, and head of
the biology/disease branch of the Human Proteome Project
(HUPO).
Lee Hartwell, Ph.D.,
President and Director Emeritus of the Fred Hutchinson Cancer
Research Center, discovered protein molecules that control the
division of cells for which he received the Nobel Prize in
Physiology and Medicine in 2001.
Joshua LaBaer, M.D.,
Ph.D. is Executive Director and Professor of the Biodesign
Institute at Arizona State University, a leading researcher in
cancer and personalized medicine, and inventor of the Nucleic Acid
Programmable Protein Array, the novel protein microarray technology
used widely for biomedical research including biomarker
discovery.
The appointment of Dr. Lundberg comes shortly after the debut of
Nautilus as a publicly traded company. Nautilus completed a
business combination with Arya Sciences Acquisition Corp III and
received gross proceeds from the transaction totaling approximately
$345 million to develop a protein analysis platform with the
potential to identify more than 95% of the proteome. Integrated
with breakthrough innovations in computer science, engineering, and
biochemistry, the Nautilus Proteomic Analysis Platform is designed
to leverage a nanofabricated, large-scale, single-molecule protein
array, multi-cycle imaging, and machine learning analysis to
measure the proteome with extreme sensitivity and scale.
About Nautilus Biotechnology, Inc.Based in
Seattle, Washington, Nautilus is a development stage life sciences
company creating a platform technology for quantifying and
unlocking the complexity of the proteome. Nautilus’ mission is to
transform the field of proteomics by democratizing access to the
proteome and enabling fundamental advancements across human health
and medicine. To learn more about Nautilus, visit
www.nautilus.bio
Special Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of federal securities laws. You can
identify forward-looking statements by words such as “may,” “will,”
“could,” “can,” “would,” “should,” “expect,” “intend,” “plan,”
“anticipate,” “believe,” “estimate,” “predict,” “project,”
“potential,” “poised,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, but not all
forward-looking statements will contain these words.
Forward-looking statements in this press release include, but are
not limited to, statements regarding the potential functionality
and performance of Nautilus’ product platform, its potential impact
on pharmaceutical development and drug discovery, and market
opportunities available to Nautilus generally. These statements are
based on numerous assumptions concerning the development of
Nautilus’ products and target markets and involve substantial
risks, uncertainties and other factors that may cause actual
results, levels of activity, performance or achievement to be
materially different from the information expressed or implied by
these forward-looking statements. We cannot assure you that the
forward-looking statements in this press release or the assumptions
upon which they are based will prove to be accurate. Risks and
uncertainties that could materially affect the accuracy of
Nautilus’ assumptions and its ability to achieve the
forward-looking statements set forth in this press release include
(without limitation) the following: Nautilus’ product platform is
not yet commercially available and remains subject to significant
scientific and technical development, which is inherently
challenging and difficult to predict, particularly with respect to
highly novel and complex products such as those being developed by
Nautilus. Even if our development efforts are successful, our
product platform will require substantial validation of its
functionality and utility in life science research. In the course
of Nautilus’ scientific and technical development and associated
product validation and commercialization, we may experience
material delays as a result of unanticipated events. We cannot
provide any guarantee or assurance with respect to the outcome of
our development and commercialization initiatives or with respect
to their associated timelines. For a more detailed description of
additional risks and uncertainties facing Nautilus and its
development efforts, investors should refer to the Registration
Statement on Form S-4 and related documents filed with the SEC. The
forward-looking statements in this press release are as of the date
of this press release. Except as otherwise required by applicable
law, Nautilus disclaims any duty to update any forward-looking
statements. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Media ContactThermal for Nautilus
BiotechnologyKaustuva Daspress@nautilus.bio
Investor
Contactinvestorrelations@nautilus.bio
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e5f02e79-12f9-4989-b93b-e1ef577ad6a7
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From Oct 2023 to Oct 2024